Action of AR-L 115 BS on myocardial oxygen consumption, cardiac performance and vascular resistance and capacitance.
2-[(2-Methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]-pyridine (AR-L 115 BS) (0.1--1.0 mg/kg i.v.) exerted positive inotropic and chronotropic actions without inducing marked elevations of myocardial oxygen consumption in anaesthetized dogs. Doses between 0.5 and 5.0 mg/kg i.v. reduced peripheral resistance by a direct vasodilating activity and increased venous capacity. Stroke volume and cardiac output were only slightly influenced by the drug. Residual and end-diastolic left ventricular volumes were reduced and ejection fraction was increased.
D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects*; D012039:Regional Blood Flow / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects*
D002316:Cardiotonic Agents; D007093:Imidazoles; C029758:sulmazole